Corrigendum: Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China

Front Public Health. 2022 Nov 9:10:1059495. doi: 10.3389/fpubh.2022.1059495. eCollection 2022.

Authors

Jia Liu^{1

2}, Lidan Cao^{1

2}, Jing Wu^{1

2}

Affiliations

¹ School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China.
² Center for Social Science Survey and Data, Tianjin University, Tianjin, China.

Abstract

[This corrects the article DOI: 10.3389/fpubh.2022.987408.].

Keywords: cost-utility; lurasidone; olanzapine; risperidone; schizophrenia.

Copyright © 2022 Liu, Cao and Wu.

Publication types

Published Erratum